UNSPSC 51182074: Testosterone phenylacetate

This classification denotes a therapeutic testosterone with the molecular formula C27H34O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WAD1QAK81D, chemically known as androst-4-en-3-one, 17-((phenylacetyl)oxy)- but more generally known as testosterone phenylacetate, which bears US NIH Compound Identifier 21925. Most nations, for tariff and trade purposes, schedule testosterone phenylacetate under HS 29372900 and SITC 54153. As of Q4 2014, TESTOSTERONE PHENYLACETATE remains US FDA's Preferred Term for this commodity.

Testosterone phenylacetate bears US NLM identifiers UMLS ID C2986926 and NCI Concept Code C95126. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CC4CCCCC4)CCC5=CC(=O)CC[C@]35C.

UNSPSC 51182074 Testosterone phenylacetate, a Commodity code, reflects state and local procurement of pharmaceutical active ingredients and finished-form medications sourced through cooperative purchasing agreements. The work involves supplying generic and branded pharmaceutical products—in this case testosterone phenylacetate among a broader portfolio of multi-source generics and over-the-counter items—to state agencies, local government facilities, and other public-sector health-care and correctional institutions. Issuing bodies under this code span state health and human services departments, state departments of administration overseeing cooperative purchasing, and participating local jurisdictions and schools within multistate cooperative frameworks. Manufacturers and authorized pharmaceutical wholesalers are the primary responders; the procurement pathway emphasizes compliance with cGMP, DSCSA, and FDA requirements, plus contractual relationships with designated drug wholesalers and chargeback-system capabilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with proposals due March 26, 2026. The solicitation spans Minnesota and Oregon and covers comprehensive pharmaceutical product lines distributed through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent combined on administrative compliance, EDI capability, and administrative-fee agreement. Vendors must maintain commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, comply with performance penalties of $200 to $1,500 per violation, and pay a 3 percent administrative fee on all contract purchases. Contract terms extend two years for new responders with optional extensions at MMCAP's sole discretion; incumbent responders' amendments align with existing expiration dates through June 30, 2028.